Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention (PRAISE-HPR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01609647|
Recruitment Status : Completed
First Posted : June 1, 2012
Last Update Posted : December 23, 2014
High platelet reactivity unit (PRU) after loading dose clopidogrel in patients undergoing percutaneous coronary intervention (PCI) is related to high risk of short and long term recurrent ischemic events including stent thrombosis.
The investigators hypothesize that additional loading of prasugrel in patients with high PRU after clopidogrel loading would be superior to additional loading of clopidogrel in reducing platelet reactivity and thereby result in lower risk of short term recurrent ischemic events.
|Condition or disease||Intervention/treatment||Phase|
|Acute Coronary Syndrome||Drug: Prasugrel Drug: Clopidogrel||Phase 3|
Dual antiplatelet therapy with acetylsalicyclic acid (ASA) and additional clopidogrel is now standard regimen for the prevention of recurrent ischemic events in patients who undergo PCI.
But decreased effect of clopidogrel in a group of patients was reported and they are known to be associated with high risk of recurrent ischemic event. Decreased effect of clopidogrel is mainly resulted from decreased function to metabolite prodrug, clopidogrel to active form of drug.
Prasugrel, newer thienopyridine has been recently developed and showed advantages to clopidogrel. Prasugrel is known to have shorter onset time to achieve steady state level than clopidogrel and constant pharmacologic effect regardless of patient diversity.
High PRU after loading dose clopidogrel in patients undergoing PCI is known to be related to increased risk of short and long term recurrent ischemic events including stent thrombosis. Prasugrel has been reported to be effective in reducing platelet reactivity in patients showing resistance to clopidogrel and high PRU.
The investigators hypothesize that additional loading of prasugrel in patients with high PRU after clopidogrel loading would be superior to additional loading of clopidogrel in reducing platelet reactivity and thereby result in reduced risk of short term recurrent ischemic events.
The investigators plan to include 70 acute coronary syndrome patients who are planned to undergo PCI and show high platelet reactivity. Most patients with ACS administer loading dose of ASA and clopidogrel as soon as they are assumed to be ACS.
The investigators plan to perform platelet reactivity test by VeryfyNow (VN) before PCI and enroll patients with high PRU defined by 235 or more. They are to randomly administered additional 300mg of clopidogrel or 20mg of prasugrel.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||76 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrel-loaded Patients Undergoing Percutaneous Coronary Intervention|
|Study Start Date :||September 2012|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
Reloading with prasugrel 20mg & followed by administration of 5mg/day for 30 days
Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
Other Name: Effient
Active Comparator: Clopidogrel
Reloading with clopidogrel 300mg and followed by administration of clopidogrel 75 mg/day for 30 days
Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
Other Name: Plavix
- HPR at 24 hours [ Time Frame: 24 hours ]Persistently high platelet reactivity after PCI. PRU is measured by methods of VerifyNow device and HPRU is defined as PRU of 240 or more.
- MACE [ Time Frame: 30 days (1 month) ]Major adverse cardiovascular events consist of cardiac death, myocardial infarction, stroke, stent thrombosis, cardiac enzyme (CRP, CK-MB, Troponin-I)
- Bleeding [ Time Frame: 30 days (1 month) ]Major, minor or minimal bleeding defined by TIMI(thrombolysis in myocardial infarction) bleeding criteria
- HPRs [ Time Frame: 4 hours after PCI, 30 days after PCI ]Persistently high platelet reactivity 4 hours and 30 days after PCI. PRU is measured by methods of VerifyNow device and HPRU is defined as PRU of 240 or more.
- Periprocedural myocardial infarction [ Time Frame: 48 hours after PCI ]Cardiac troponin value is >5x99th percentile upper reference plus either (1) evidence of prolonged ischaemic chest pain (>20min) or (2) ischaemic ST changes or new pathological Q waves, or (3) angiographic evidence of a side branch occlusion, slow-flow or no-reflow, embolization, or (4) imaging evidence of new regional wall motion abnormality.
- Periprocedural myocardial injury [ Time Frame: 48 hours after PCI ]Cardiac troponin (cTn) value is ≤5x99th percentile upper reference limit (URL) after PCI and cTn value was normal before the PCI or cTn value is >5x99th percentile URL in absence of ischaemic chest pain or ST changes, with normal angiographic and imaging findings.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01609647
|Korea, Republic of|
|DongA University Hospital|
|Busan, Korea, Republic of, 602-715|
|Principal Investigator:||Moo Hyun Kim, MD||Director, Regional Clinical Trial Center|